Effect of Radiotherapy on T Cell and PD-1 / PD-L1 Blocking Therapy in Tumor Microenvironment

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 Jan 11

PMID 33428533

Citations 15

Authors

Chen Chen

Yanlong Liu

Binbin Cui

Affiliations

Soon will be listed here.

Abstract

Cancer is a worldwide problem that threatens human health. Radiotherapy plays an important role in a variety of cancer treatment methods. The administration of radiotherapy can alter the differentiation pathways and functions of T cells, which in turn improves the immune response of T cells. Radiotherapy can also induce up-regulation of PD-L1 expression, which means that it has great potential for enhancing the therapeutic effect of anti-PD-1/PD-L1 inhibitors and reducing the risk of drug resistance toward them. At present, the combination of radiotherapy and anti-PD-1/PD-L1 inhibitors has shown significant therapeutic effects in clinical tumor research. This review focuses on the mechanism of radiotherapy on T cells reported in recent years, as well as related research progress in the application of PD-1/PD-L1 blockers. It will provide a theoretical basis for the rational clinical application of radiotherapy combined with PD-1/PD-L1 inhibitors.

Citing Articles

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Shi X, Zhao H, Yu J, Cai P, Zhou S, Yang N Ann Med. 2024; 57(1):2445190.

PMID: 39713872 PMC: 11703528. DOI: 10.1080/07853890.2024.2445190.

Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer.

Wang M, Li S, Li R, Ning F, Tian L Curr Treat Options Oncol. 2024; 25(12):1605-1614.

PMID: 39625619 PMC: 11638397. DOI: 10.1007/s11864-024-01260-x.

Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study.

Wang F, Lai C, Lv Y, Zhang F, Shi L, Wang Y Int J Surg. 2024; 111(1):334-345.

PMID: 39093871 PMC: 11745671. DOI: 10.1097/JS9.0000000000001960.

HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy.

Balci Topuz B, Sert F, Sezak M, Soylu M, Yalman D, Ozkok S Oncol Lett. 2024; 28(2):395.

PMID: 38966586 PMC: 11223008. DOI: 10.3892/ol.2024.14528.

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

References

Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neumann-Haefelin C . TCF1 hepatitis C virus-specific CD8 T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017; 8:15050. PMC: 5418623. DOI: 10.1038/ncomms15050. View

Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A . In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med. 2015; 7(273):273ra13. DOI: 10.1126/scitranslmed.3010314. View

Ciucci T, Vacchio M, Bosselut R . A STAT3-dependent transcriptional circuitry inhibits cytotoxic gene expression in T cells. Proc Natl Acad Sci U S A. 2017; 114(50):13236-13241. PMC: 5740647. DOI: 10.1073/pnas.1711160114. View

Ganesan A, Clarke J, Wood O, Garrido-Martin E, Chee S, Mellows T . Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017; 18(8):940-950. PMC: 6036910. DOI: 10.1038/ni.3775. View

Brummelman J, Mazza E, Alvisi G, Colombo F, Grilli A, Mikulak J . High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors. J Exp Med. 2018; 215(10):2520-2535. PMC: 6170179. DOI: 10.1084/jem.20180684. View

Gato-Canas M, Arasanz H, Blanco-Luquin I, Glaria E, Arteta-Sanchez V, Kochan G . Novel immunotherapies for the treatment of melanoma. Immunotherapy. 2016; 8(5):613-32. DOI: 10.2217/imt-2015-0024. View

Ratti M, Lampis A, Hahne J, Passalacqua R, Valeri N . Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018; 75(22):4151-4162. PMC: 6182336. DOI: 10.1007/s00018-018-2906-9. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Billiard F, Buard V, Benderitter M, Linard C . Abdominal γ-radiation induces an accumulation of function-impaired regulatory T cells in the small intestine. Int J Radiat Oncol Biol Phys. 2011; 80(3):869-76. DOI: 10.1016/j.ijrobp.2010.12.041. View

10.

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

11.

Darragh L, Oweida A, Karam S . Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. Front Immunol. 2019; 9:3154. PMC: 6366147. DOI: 10.3389/fimmu.2018.03154. View

12.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

13.

Shevtsov M, Sato H, Multhoff G, Shibata A . Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol. 2019; 9:156. PMC: 6433964. DOI: 10.3389/fonc.2019.00156. View

14.

Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A . Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thorac Cancer. 2019; 10(4):992-1000. PMC: 6449241. DOI: 10.1111/1759-7714.13044. View

15.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

16.

Marcus A, Mao A, Lensink-Vasan M, Wang L, Vance R, Raulet D . Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018; 49(4):754-763.e4. PMC: 6488306. DOI: 10.1016/j.immuni.2018.09.016. View

17.

Michot J, Mazeron R, Dercle L, Ammari S, Canova C, Marabelle A . Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer. 2016; 66:91-4. DOI: 10.1016/j.ejca.2016.06.017. View

18.

Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J . Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017; 8(1):1136. PMC: 5656607. DOI: 10.1038/s41467-017-01062-w. View

19.

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

20.

Maity A, Mick R, Huang A, George S, Farwell M, Lukens J . A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018; 119(10):1200-1207. PMC: 6251028. DOI: 10.1038/s41416-018-0281-9. View